Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04599010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Aug 31, 2026 to Jul 31, 2027
Study completion date: Feb 28, 2027 to Dec 31, 2027
v19
NotableStart date: Aug 27, 2024 to Sep 26, 2024
Primary completion date: May 1, 2026 to Aug 31, 2026
Study completion date: Jun 1, 2026 to Feb 28, 2027
v18
MinorSite details revised at 1 of 2 sitesv17
NotableTrial status: Not Yet Recruiting to Recruiting
Start date changed from estimate of Sep 1, 2024 to Aug 27, 2024
Site details revised at 2 of 2 sites
v16
MinorStart date: Aug 10, 2024 to Sep 1, 2024v15
Show 13 earlier versionsHide 13 earlier versions
MinorStart date: Jul 15, 2024 to Aug 10, 2024v14
MinorPrimary completion date: May 2026 to May 1, 2026
Study completion date: Jun 2026 to Jun 1, 2026
v13
NotableStart date: May 15, 2024 to Jul 15, 2024
Study sites revised (2)
Collaborator revised
v12
NotableStart date: Mar 15, 2024 to May 15, 2024v11
NotableStart date: Jan 15, 2024 to Mar 15, 2024v10
NotableStart date: Oct 1, 2023 to Jan 15, 2024v9
NotableStart date: Aug 1, 2023 to Oct 1, 2023
Primary completion date: May 31, 2026 to May 2026
Study completion date: Jul 31, 2026 to Jun 2026
v8
NotablePrimary completion date: Jun 30, 2025 to May 31, 2026
Start date: Apr 1, 2023 to Aug 1, 2023
Study completion date: Mar 31, 2026 to Jul 31, 2026
v7
NotablePrimary endpoint revised
Eligibility criteria revised
Study title revised
v6
NotablePhase: Phase 2/3 to Not applicablev5Show 7 more changesShow less
Primary completion date: Jun 30, 2024 to Jun 30, 2025
Start date: Jul 1, 2022 to Apr 1, 2023
Primary endpoint revised
Study completion date: Dec 30, 2024 to Mar 31, 2026
Eligibility criteria revised
Secondary endpoints: 4 to 6
Study description revised
NotablePhase: Not applicable to Phase 2/3v4
MinorRe-verified, no change to tracked fieldsv3
NotablePrimary completion date: Jun 30, 2023 to Jun 30, 2024v2Show 9 more changesShow less
Start date: Sep 1, 2021 to Jul 1, 2022
Primary endpoint revised
Enrollment target: 30 to 40
Study sites: 0 to 2
Study completion date: Aug 30, 2023 to Dec 30, 2024
Eligibility criteria expanded, about 15 words
Secondary endpoints: 3 to 4
Study description expanded, about 85 words
Study title expanded, about 5 words
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Large for Gestational Age (LGA) infants have excess fat-mass (FM) proportion secondary to prolonged in utero exposure to an energy-rich environment. Our preliminary data suggest that excess FM proportion can be associated with oral feeding delay and a potentially modifiable therapeutic target to improve oral feeding outcomes. The objective of this study is to determine the impact of a short-term Fat-free mass (FFM)-indexed feeding on the oral intake volumes in LGA infants with oral feeding difficulties.